Bayer Acquires Perfuse Therapeutics in $2.45 Billion Deal for Ocular Pipeline Asset PER-001

Bayer's $2.45 billion acquisition of Perfuse Therapeutics transfers full development and commercialisation rights for PER-001 to one of pharma's largest ophthalmology franchises, a move that will reshape formulation and manufacturing expectations across the ocular drug delivery supply chain. For contract development and manufacturing organisations already active in sterile ophthalmic dosage forms, the deal signals an accelerated timeline and a more demanding quality posture ahead.

PER-001 is currently in Phase II clinical trials for glaucoma and diabetic retinopathy, two indications with substantial unmet need and well-documented regulatory complexity under 21 CFR Part 211 and ICH Q10 quality system expectations. Bayer's integration of the asset means process validation planning, analytical method transfers, and sterility assurance protocols will need to align with the acquirer's existing GMP infrastructure, a transition that typically surfaces gaps in documentation and supplier qualification.

The scale of the deal reflects a broader pattern among large pharmaceutical companies: rebuilding late-stage ophthalmology pipelines through acquisition rather than internal discovery. For QA directors and regulatory affairs leads at CDMOs or formulation partners already engaged with ocular biologics or small-molecule delivery platforms, Bayer's entry into this asset class raises the bar on technology transfer readiness and batch record integrity.

Supply-chain implications are direct: Perfuse's existing manufacturing relationships will face reassessment against Bayer's vendor qualification standards, and any gaps in process characterisation data will require remediation before Phase III scale-up can proceed. Regulatory affairs teams should anticipate that Bayer will pursue alignment with FDA and EMA early, particularly around the IND/CTA amendments required to reflect the change in sponsor.

The Phase II readout for PER-001 across both indications will serve as the first measurable checkpoint for Bayer's return on this investment and the clearest signal of whether the asset's clinical profile can support a registrational programme.

Source: Media4Growth via Indian Pharma Post, 6 May 2026.